

Contact:

Douglas Doerfler
Chief Executive Officer
TheraMed, Inc.
(301) 517-5556

Megan E. Burling
Feinstein Kean Healthcare
www.fkhealth.com
(202) 452-7810

For Immediate Release

TheraMed Strengthens Board of Directors and Scientific Advisory Board with Key Appointments

Rockville, MD, June 26, 2001 -- TheraMed, Inc. today announced the appointments of J. Stark Thompson, Ph.D. to its Board of Directors and Malcolm K. Brenner, M.D., Ph.D. to its Scientific Advisory Board. Dr. Thompson is the former President and CEO of Life Technologies Inc. Dr. Brenner is currently a Professor of Medicine and Director, Center for Cell and Gene Therapy at Baylor College of Medicine and President of the American Society for Gene Therapy.

"During his tenure at Life Technologies, the Company became a leading developer, manufacturer, and supplier of products and services to the life sciences industry worldwide, while more than tripling its revenues and increasing shareholder value by nearly 900%. Dr. Thompson's extensive management experience combined with his scientific expertise in the area of instrumentation for life sciences will be invaluable to TheraMed as the Company continues to grow and expands its clinical development programs," said Doug Doerfler, Chief Executive Officer of TheraMed, Inc.

Dr. Thompson has over thirty years of experience in life sciences technology development and commercialization. From 1988 to year 2000, Dr. Thompson has served as President and Chief Executive Officer of Life Technologies Inc. and was on the Executive Committee of its largest shareholder Dexter Corporation. Prior to joining Life Technologies, Dr. Thompson served in multiple positions of increasing responsibility over a period of 21 years at DuPont de Nemours and Co., a diversified chemical company. Dr. Thompson held numerous positions at DuPont de Nemours and Co. such as Business Director of the Clinical Systems Division, Manager of the Instruments Systems Division and Manager of Health Care Business Planning. Dr. Thompson received his B.S. in Chemistry from Muskingum College and Ph.D. in Physiological Chemistry from Ohio State University. Dr. Thompson is currently a member of the Executive Committees of several educational and non-profit organizations.

Commenting on Dr. Brenner's appointment, TheraMed's Chief Medical Officer, Joseph Fratantoni, M.D. said, "We are honored to add someone with Dr. Brenner's extensive research background and considerable experience as a pioneer in the field of gene and cell therapy to our Scientific Advisory Board. Dr. Brenner's counsel will help enable TheraMed to attain a leadership position in the field of gene therapy and advance our non-viral gene products for the treatment of genetic disorders and cancer."

Dr. Brenner is Professor of Medicine and of Pediatrics and Director, Center for Cell and Gene Therapy at Baylor College of Medicine. From 1994 to 1997 he was Director, Cell and Gene Therapy Program, St. Jude Children's Research Hospital. Previously Dr. Brenner was Professor, Departments of Pediatrics and Medicine at the University of Tennessee, and Director, Bone Marrow Transplant Division, and Member, Department Hematology/Oncology at St. Jude Children's Research Hospital. In 1992 he was awarded the ALSAC Chair in Transplantation Research. Dr. Brenner has authored over 150 original research papers and has served as a member of the FDA Advisory Committee on Biological Response Modifiers, the National Gene Vector Laboratory Steering Committee and the National Cancer Institute Clinical Trials Program Review Committee. He is a past President of the International Society of Hematotherapy and Graft Engineering and is the current President of the American Society for Gene Therapy. Dr. Brenner received his B.A., M.D. and Ph.D. from Cambridge University, England.

TheraMed, Inc., is a clinical stage biotechnology company developing targeted therapeutic products to treat severe and chronic diseases, including cancer, serious infections, cardiovascular disease and genetic disorders, based on its proprietary technology that uses blood cells for drug and non-viral gene delivery. TheraMed is majority owned by Entremed, Inc. For further information, please visit the TheraMed web site at <http://www.TheraMedInc.com>.

Entremed, Inc., The Angiogenesis Company(TM), NASDAQ (ENMD) is a clinical-stage biopharmaceutical company emphasizing antiangiogenesis therapeutics that inhibit abnormal blood vessel growth associated with a broad range of diseases such as cancer, blindness and atherosclerosis. The company's strategy is to accelerate development of its core technologies through collaborations and sponsored research programs with university medical departments, research companies and government laboratories. For further information, please visit the Entremed web site at <http://www.entremed.com>.

This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.

#####